Precision Optics Corporation Announces Receipt of Notice From Nasdaq

Dec 21, 2005, 00:00 ET from Precision Optics Corporation

    GARDNER, Mass., Dec. 21 /PRNewswire-FirstCall/ -- Precision Optics
 Corporation, Inc. (Nasdaq:   POCI) today announced receipt of a Nasdaq Staff
 Determination letter, dated December 15, 2005, from The Nasdaq Stock Market
 ("Nasdaq") indicating the Company's securities will be delisted from The
 Nasdaq Capital Market at the opening of business on December 27, 2005.  Nasdaq
 has determined that the Company is not in compliance with Nasdaq's
 requirements for continued listing as the Company's shareholders equity amount
 is below the minimum requirement of $2.5 million specified by Marketplace Rule
 4310(c)(2)(B).  In addition, the Company's stock does not meet the $1.00 per
 share minimum bid price requirement for continued listing set forth in
 Marketplace Rule 4310(c)(4).  The Company submitted a plan of compliance to
 Nasdaq Staff, however, Staff's determination was that the proposed plan lacked
 sufficient evidence of the ability to achieve near term compliance with
 continued listing requirements or sustain such compliance over an extended
 period of time.  The Company has decided not to appeal Nasdaq's determination.
 Accordingly, the Company's securities will be delisted as provided in the
 Nasdaq Staff Determination letter.
     We expect that our common stock will be quoted on the "Pink Sheets."  The
 Company will also seek to have its common stock quoted on the Over-The-Counter
 Market on the NASD Electronic Bulletin Board (OTCBB).  Information regarding
 the Company's stock and stock trading is expected to remain available via the
 Nasdaq website, through on-line trading services and through securities
 brokers under the symbol POCI.
     About Precision Optics
     Precision Optics Corporation, a leading developer and manufacturer of
 advanced optical instruments since 1982, designs and produces high-quality
 optical thin film coatings, medical instruments, and other advanced optical
 systems.  The Company's medical instrumentation line includes laparoscopes,
 arthroscopes and endocouplers and a world-class product line of 3-D endoscopes
 for use in minimally invasive surgical procedures.
     The Company is currently developing specialty instruments incorporating
 its patent-pending Lenslock(TM) technology which ensures lower cost, easier
 repairability and enhanced durability.  The Company is aggressively pursuing
 ultra-small instruments (some with lenses less than one millimeter in
 diameter) utilizing patent pending micro-precision(TM) lens technology.  The
 Company is also exploring new initiatives in single molecule technology and
 nanotechnology for biomedical and other applications.
     Precision Optics Corporation is certified to the ISO 9001 Quality
 Standard, and complies with the FDA Good Manufacturing Practices and the
 European Union Medical Device Directive for CE Marking of its medical
 products.  The Company's Internet Website is .
     Forward-looking statements contained in this news release, including those
 related to the Company's products under development and revenue estimates, are
 made under "safe harbor" provisions of the Private Securities Litigation
 Reform Act of 1995 and involve a number of risks and uncertainties that could
 materially affect future results. These risks and uncertainties, many of which
 are not within the Company's control, include, but are not limited to, the
 uncertainty and timing of the successful development of the Company's new
 products; the risks associated with reliance on a few key customers; the
 Company's ability to regain and maintain compliance with requirements for
 continued listing on the NASDAQ Capital Market; the Company's ability to
 attract and retain personnel with the necessary scientific and technical
 skills, the timing and completion of significant orders; the timing and amount
 of the Company's research and development expenditures; the timing and level
 of market acceptance of customers' products for which the Company supplies
 components; performance of the Company's vendors; the ability of the Company
 to control costs associated with performance under fixed price contracts; and
 the continued availability to the Company of essential supplies, materials and
 services; and the other risk factors and cautionary statements listed from
 time to time in the Company's periodic reports filed with the Securities and
 Exchange Commission, including but not limited to, the Company's Annual Report
 on Form 10-KSB for the year ended June 30, 2005.

SOURCE Precision Optics Corporation